Clinical Trials
11 trialsNCT06866548 2025-12-04
Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Shanghai Changzheng Hospital
Phase EARLY_PHASE1 Active not recruiting
NCT00889382 2024-11-20
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Astellas Pharma Inc
Phase 1/2 Completed
NCT00924989 2024-11-20
GALACCTIC
Astellas Pharma Inc
Phase 3 Completed
NCT00630552 2024-10-17
QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer
NantCell, Inc.
Phase 1/2 Completed
NCT00807612 2024-09-25
QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
NantCell, Inc.
Phase 1/2 Terminated
NCT04767750 2022-04-07
Role of LncRNA H19 in The Regulation of IGF-1R Expression
Mansoura University
Completed
NCT00684983 2020-03-24
Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00563680 2016-10-27
QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors
NantCell, Inc.
Phase 2 Completed
NCT01733004 2016-08-04
A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors
Merrimack Pharmaceuticals
Phase 1 Completed
NCT00799240 2014-11-07
IMPACT
University of Kansas Medical Center
Phase 2 Completed
NCT00956436 2013-09-16
Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
Biogen
Phase 1 Completed